# A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

> **NCT02180269** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-54861911 (25 mg)
- **DRUG:** JNJ-54861911 (50 mg)
- **DRUG:** JNJ-54861911 (100 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02180269
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02180269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02180269, "A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02180269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*